Switzerland | Exports | USA | Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products | Value (US$) and Value Growth, YoY (%) | 2012 - 2023
| Commodity | Reporter | Partner | Trade flow | Indicator | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
| 3002. Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc | Switzerland | USA | Exports | Value (US$) | 2,877,635,360.00 | 3,300,972,685.98 | 3,803,298,968.28 | 3,945,307,395.06 | 4,778,100,563.97 | 5,867,116,099.16 | 7,255,396,912.85 | 10,169,962,395.68 | 11,671,617,269.92 | 13,701,508,314.16 | 16,040,910,458.66 | 17,034,126,063.94 |
| Value Growth, YoY (%) | 5.19 | 14.71 | 15.21 | 3.73 | 21.10 | 22.79 | 23.66 | 40.17 | 14.76 | 17.39 | 17.07 | 6.19 |
The value of exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" from Switzerland to USA totalled $ 17 billion in 2023. Sales of commodity group 3002 from Switzerland to USA increased by 6.19% compared to 2022: exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" went up by $ 993 million (exports of commodity group 3002 from Switzerland to USA were equal to $16 billion in 2022)
Exports of "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" from Switzerland to USA accounted for 27% of the total merchandise exports in 2023 (total sales of goods from Switzerland to USA were equal to $ 62 billion in 2023). The share of commodity group 3002 grew up by 2.45 p.p. in overall exports from Switzerland to USA compared to 2022 (it was 24% in 2022 and cumulative exports from Switzerland to USA were equal to $ 65 billion).
Exports of commodity group 3002 accounted for 55% of total sales of commodity group "" from Switzerland to USA in 2023 (cumulative exports of commodity group from Switzerland to USA were equal to $30 billion in 2023). The share of exports of commodity group 3002 in sales of commodity group from Switzerland to USA went up by 2.24 p.p. compared to 2022 (it was 53% in 2022, and exports of commodity group from Switzerland to USA were $30 billion).
The share of USA in total exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" from Switzerland was 32 percent (17 billion USD) in 2023 of 52 billion USD - the value of overall merchandise exports of commodity group 3002 from Switzerland in 2023. The share of USA in exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" from Switzerland grew up by 0.442 p.p. in value terms compared to 2022 (it was 32 percent in 2022, and overall exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" from Switzerland amounted to 50 billion USD).
